Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-κB

被引:38
|
作者
Bai, Yangqiu [1 ]
Zhang, Lida [1 ]
Fang, Xinhui [1 ]
Yang, Yuxiu [1 ]
机构
[1] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Gastroenterol, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China
关键词
tanshinone IIA; chemosensitization; cell death; nuclear factor-kappa B; colon cancer; SIGNALING PATHWAY; INDUCED APOPTOSIS; IN-VITRO; ACTIVATION; RESISTANCE; INHIBITION; INDUCTION; EXTRACT; GROWTH; PROLIFERATION;
D O I
10.3892/etm.2016.2984
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the present study was to investigate the effect and molecular mechanism of tanshinone IIA (TSA) on colon cancer cells. Cell viability was determined using Cell Counting kit-8 assay and the results demonstrated that TSA treatment significantly decreased the cell viability of HCT1116 and COLO205 cells in a dose-dependent manner. TSA treatment also sensitized HCT1116 and COLO205 cells to fluorouracil therapy in a concentration-dependent manner. Western blotting was performed in order to investigate the molecular mechanisms of TSA action and determine the level of phosporylated p65 and nuclear factor-kappa B (NF-kappa B)-regulated genes, including vascular endothelial growth factor (VEGF), c-Myc, cyclooxygenase-2 (COX-2) and B-cell lymphoma-2 (Bcl-2). The results revealed that TSA treatment greatly decreased the level of phosphorylated p65 in the nucleus, which indicated the inhibition of NF-kappa B activation by TSA treatment. TSA also decreased the expression levels of VEGF, c-Myc, COX-2 and Bcl-2. Furthermore, the inhibition of NF-kappa B activation with the specific inhibitor, pyrrolidine dithiocarbamate, increased the induction of cell death and chemosensitization effect of TSA in colon cancer cells. In conclusion, these results suggest that TSA induces cell death and chemosensitizes colon cancer cells through the suppression of NF-kappa B signaling.
引用
收藏
页码:1085 / 1089
页数:5
相关论文
共 50 条
  • [21] Identification of a novel blocker of IκBα kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-κB
    Sung, Bokyung
    Pandey, Manoj K.
    Nakajima, Yuki
    Nishida, Hiroshi
    Konishi, Tetsuya
    Chaturvedi, Madan M.
    Aggarwal, Bharat B.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 191 - 201
  • [22] Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor- by inhibiting the nuclear factor-κB signaling pathway
    Zhu, Jing
    Xin, Ying
    Liu, Xiaoliang
    Wang, Ying
    Liu, Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (04) : 3345 - 3351
  • [23] Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation
    Li, Shizheng
    Wu, Chunxia
    Fan, Chenxing
    Zhang, Puwei
    Yu, Guifa
    Li, Kun
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (01)
  • [24] Nuclear factor-κB is upregulated in colorectal cancer
    Lind, DS
    Hochwald, SN
    Malaty, J
    Rekkas, S
    Hebig, P
    Mishra, G
    Moldawer, LL
    Copeland, EM
    MacKay, S
    SURGERY, 2001, 130 (02) : 363 - 369
  • [25] Nuclear factor-κB in cancer development and progression
    Michael Karin
    Nature, 2006, 441 : 431 - 436
  • [26] Nuclear factor-κB in cancer development and progression
    Karin, Michael
    NATURE, 2006, 441 (7092) : 431 - 436
  • [27] Adiponectin protects Leydig cells against proinflammatory cytokines by suppressing the nuclear factor-κB signaling pathway
    Wu, Ling
    Xu, Bufang
    Fan, Weimin
    Zhu, Xiaobin
    Wang, Guangyan
    Zhang, Aijun
    FEBS JOURNAL, 2013, 280 (16) : 3920 - 3927
  • [28] MiR-302a Limits Vascular Inflammation by Suppressing Nuclear Factor-κ B Pathway in Endothelial Cells
    Yuan, Jia-Ni
    Hong, Yu
    Ma, Zhuo-Lin
    Pang, Rui-Ping
    Lei, Qing-Qing
    Lv, Xiao-Fei
    Zhou, Jia-Guo
    Huang, Hui
    Zhang, Ting-Ting
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [29] Nuclear factor-κB
    Zingarelli, B
    CRITICAL CARE MEDICINE, 2005, 33 (12) : S414 - S416
  • [30] Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
    Khanbolooki, Sanaz
    Nawrocki, Steffan T.
    Arumugam, Thiruvengadam
    Andtbacka, Robert
    Pino, Maria S.
    Kurzrock, Razelle
    Logsdon, Craig D.
    Abbruzzese, James L.
    McConkey, David J.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) : 2251 - 2260